Summit Therapeutics (SMMT)
NASDAQ:SMMT
Total Valuation
Summit Therapeutics has a market cap or net worth of $14.49B. The enterprise value is $13.71B.
Market Cap$14.49B
Enterprise Value$13.71B
Share Statistics
Summit Therapeutics has 775,372,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding775,372,700
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Summit Therapeutics’s return on equity (ROE) is -1.64 and return on invested capital (ROIC) is -159.98%.
Return on Equity (ROE)-1.64
Return on Assets (ROA)-1.44
Return on Invested Capital (ROIC)-159.98%
Return on Capital Employed (ROCE)-1.61
Revenue Per Employee0.00
Profits Per Employee-6.79M
Employee Count159
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Summit Therapeutics is ―. Summit Therapeutics’s PEG ratio is -0.03.
PE Ratio―
PS Ratio0.00
PB Ratio19.85
Price to Fair Value19.85
Price to FCF-40.41
Price to Operating Cash Flow-43.27
PEG Ratio-0.03
Income Statement
In the last 12 months, Summit Therapeutics had revenue of 0.00 and earned -1.08B in profits. Earnings per share was -1.44.
Revenue0.00
Gross Profit-108.36K
Operating Income-1.09B
Pretax Income-1.08B
Net Income-1.08B
EBITDA-801.12M
Earnings Per Share (EPS)-1.44
Cash Flow
In the last 12 months, operating cash flow was -322.93M and capital expenditures -657.00K, giving a free cash flow of -323.59M billion.
Operating Cash Flow-322.93M
Free Cash Flow-323.59M
Free Cash Flow per Share-0.42
Dividends & Yields
Summit Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.67
52-Week Price Change12.32%
50-Day Moving Average15.92
200-Day Moving Average19.83
Relative Strength Index (RSI)62.54
Average Volume (3m)2.49M
Important Dates
Summit Therapeutics upcoming earnings date is May 7, 2026, After Close (Confirmed).
Last Earnings DateFeb 23, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Summit Therapeutics as a current ratio of 9.87, with Debt / Equity ratio of 3.17%
Current Ratio9.87
Quick Ratio9.87
Debt to Market Cap<0.01
Net Debt to EBITDA0.26
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Summit Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Summit Therapeutics EV to EBITDA ratio is -16.07, with an EV/FCF ratio of -39.78.
EV to Sales0.00
EV to EBITDA-16.07
EV to Free Cash Flow-39.78
EV to Operating Cash Flow-39.86
Balance Sheet
Summit Therapeutics has $713.45M in cash and marketable securities with $20.89M in debt, giving a net cash position of $692.56M billion.
Cash & Marketable Securities$713.45M
Total Debt$20.89M
Net Cash$692.56M
Net Cash Per Share$0.89
Tangible Book Value Per Share$0.88
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Summit Therapeutics is $31.78, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$31.78
Price Target Upside70.04% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast―
EPS Growth Forecast-348.63%